Is OTLK or AURA more profitable?

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Aura Biosciences N/A -78.12% -64.08%

Is OTLK or ALLO more profitable?

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Allogene Therapeutics N/A -56.45% -40.36%

Is CLYM or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Oncobiologics N/A N/A -291.28%

Does the media prefer CLYM or OTLK?

In the previous week, Climb Bio had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Climb Bio's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCS or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Oncobiologics N/A N/A -291.28%

Does the media prefer OCS or OTLK?

In the previous week, Oculis had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Oculis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CADL or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Oncobiologics N/A N/A -291.28%

Does the media prefer CADL or OTLK?

In the previous week, Candel Therapeutics had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Candel Therapeutics' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncobiologics (OTLK) Competitors

$1.68 -0.02 (-1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.18%)

As of 08:00 PM Eastern

Compare

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include Aura Biosciences (AURA), Allogene Therapeutics (ALLO), Climb Bio (CLYM), Oculis (OCS), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Oncobiologics compare to Aura Biosciences?

Oncobiologics (NASDAQ:OTLK) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Oncobiologics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Oncobiologics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat Oncobiologics' score of 0.67 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Positive
Aura Biosciences	Positive

Oncobiologics currently has a consensus target price of $6.50, indicating a potential upside of 286.90%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 191.19%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Summary

Oncobiologics beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Oncobiologics compare to Allogene Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Oncobiologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A
Allogene Therapeutics	$20K	35,377.88	-$190.89M	-$0.77	N/A

Oncobiologics currently has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 315.72%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, Oncobiologics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Allogene Therapeutics. Oncobiologics' average media sentiment score of 0.67 beat Allogene Therapeutics' score of -1.74 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Overall Sentiment
Oncobiologics	Positive
Allogene Therapeutics	Very Negative

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Allogene Therapeutics beats Oncobiologics on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Climb Bio had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Climb Bio's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Oncobiologics	N/A	N/A	-291.28%

Climb Bio has higher earnings, but lower revenue than Oncobiologics. Climb Bio is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A

Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Climb Bio currently has a consensus target price of $21.73, indicating a potential upside of 70.41%. Oncobiologics has a consensus target price of $6.50, indicating a potential upside of 286.90%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Climb Bio beats Oncobiologics on 9 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Oculis?

Oculis (NASDAQ:OCS) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Oculis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	462.24	-$119.44M	-$2.13	N/A
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A

In the previous week, Oculis had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Oculis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Oncobiologics	N/A	N/A	-291.28%

22.3% of Oculis shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oculis presently has a consensus target price of $38.33, indicating a potential upside of 231.60%. Oncobiologics has a consensus target price of $6.50, indicating a potential upside of 286.90%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oncobiologics beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Candel Therapeutics has a beta of -0.49, meaning that its share price is 149% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Oncobiologics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Oncobiologics	N/A	N/A	-291.28%

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Candel Therapeutics has higher earnings, but lower revenue than Oncobiologics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A

In the previous week, Candel Therapeutics had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Candel Therapeutics' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 94.17%. Oncobiologics has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Candel Therapeutics beats Oncobiologics on 8 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$238.08M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-1.44	20.50	25.39	23.96
Price / Sales	174.28	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-2.80	8.26	10.76	6.41
Net Income	-$62.42M	$23.91M	$3.56B	$337.14M
7 Day Performance	1.82%	3.05%	1.37%	-0.48%
1 Month Performance	442.11%	2.40%	0.81%	0.49%
1 Year Performance	-5.08%	56.35%	30.53%	28.16%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.5878 of 5 stars	$1.68 -1.2%	$6.50 +286.9%	+1.2%	$238.08M	$1.35M	N/A	20	Gap Up
AURA Aura Biosciences	2.9211 of 5 stars	$6.45 +0.6%	$20.50 +217.8%	+14.1%	$662.71M	N/A	N/A	50
ALLO Allogene Therapeutics	2.3484 of 5 stars	$1.94 +2.1%	$8.52 +339.3%	+69.7%	$655.79M	$20K	N/A	310
CLYM Climb Bio	3.1914 of 5 stars	$11.49 +0.4%	$21.73 +89.1%	+925.0%	$655.09M	N/A	N/A	9	Analyst Forecast
OCS Oculis	2.8447 of 5 stars	$11.61 +4.7%	$38.33 +230.2%	-40.4%	$643.05M	$1.45M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

How does Oncobiologics compare to Aura Biosciences?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Summary

How does Oncobiologics compare to Climb Bio?

Summary

How does Oncobiologics compare to Oculis?

Summary

How does Oncobiologics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

How does Oncobiologics compare to Aura Biosciences?

Which has higher valuation and earnings, OTLK or AURA?

Do institutionals & insiders believe in OTLK or AURA?

Is OTLK or AURA more profitable?

Does the media refer more to OTLK or AURA?

Do analysts prefer OTLK or AURA?

Which has more risk and volatility, OTLK or AURA?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Which has preferable earnings and valuation, OTLK or ALLO?

Do analysts prefer OTLK or ALLO?

Do insiders & institutionals hold more shares of OTLK or ALLO?

Which has more risk and volatility, OTLK or ALLO?

Does the media refer more to OTLK or ALLO?

Is OTLK or ALLO more profitable?

Summary

How does Oncobiologics compare to Climb Bio?

Does the media prefer CLYM or OTLK?

Is CLYM or OTLK more profitable?

Which has stronger earnings and valuation, CLYM or OTLK?

Which has more risk & volatility, CLYM or OTLK?

Do analysts rate CLYM or OTLK?

Do institutionals & insiders believe in CLYM or OTLK?

Summary

How does Oncobiologics compare to Oculis?

Which has more volatility and risk, OCS or OTLK?

Which has preferable earnings & valuation, OCS or OTLK?

Does the media prefer OCS or OTLK?

Is OCS or OTLK more profitable?

Do insiders and institutionals believe in OCS or OTLK?

Do analysts rate OCS or OTLK?

Summary

How does Oncobiologics compare to Candel Therapeutics?

Which has more volatility & risk, CADL or OTLK?

Is CADL or OTLK more profitable?

Do insiders and institutionals have more ownership in CADL or OTLK?

Which has better earnings and valuation, CADL or OTLK?

Does the media prefer CADL or OTLK?

Do analysts prefer CADL or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools